Leap Therapeutics, Inc. (LPTX)
| Market Cap | 82.35M |
| Revenue (ttm) | 1.50M |
| Net Income (ttm) | -29.42M |
| Shares Out | 76.38M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $1.41 |
| Previous Close | $1.35 |
| Change ($) | 0.06 |
| Change (%) | 4.44% |
| Day's Open | 1.34 |
| Day's Range | 1.34 - 1.44 |
| Day's Volume | 134,008 |
| 52-Week Range | 1.33 - 3.24 |
CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Compan...
Leap Therapeutics, Inc. (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin...
CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dougla...
CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dougl...
Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of -9.09% and -3.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., May 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial re...
CAMBRIDGE, Mass. and WESTMINSTER, Colo.
Leap Therapeutics, Inc. (LPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benjamin Graham, the pioneer of value investing, proposed to look for stocks that have a current ratio of more than 2 and more working capital than long-term debt.
WESTMINSTER, Colo. and CAMBRIDGE, Mass.
CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the comple...
Leap Therapeutics Stock Is Trading Higher After Encouraging DKN-01 Data At Gynecologic Oncology Meet
Leap Therapeutics Inc (NASDAQ: LPTX) has announced the presentation of clinical data from its Phase 2 clinical trial of DKN-01 as a monotherapy and in combination with paclitaxel in patients with advanc...
CAMBRIDGE, Mass., March 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the prese...
Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of -12.50% and -6.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial ...
CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dougl...
CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the public...
CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dougl...
CAMBRIDGE, Mass., Nov. 10, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Dougl...
CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the present...
Two new breakout stocks for Week 46 with better than 10% short-term upside potential. This past week three out of four stocks gained more than 10% closing with gains to Friday with AVNS +8.54%, IMVT +14...
CAMBRIDGE, Mass., Sept. 24, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the ...
CAMBRIDGE, Mass. and BEIJING, Sept. 21, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and BeiGene, ...
CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 13, 2020 /PRNewswire/ -- Leap Therapeutics, Inc.
CAMBRIDGE, Mass., June 25, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closi...
CAMBRIDGE, Mass., June 17, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it ha...
Leap Therapeutics (LPTX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U...
CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, due...
CAMBRIDGE, Mass., May 14, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial r...
Facing a de-listing from NASDAQ and forced to abandon its second clinical asset due to a cash crunch, Leap has rebounded somewhat on the back of a collaboration/financing deal.
Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.
Leap Therapeutics (LPTX) news for Friday has LPTX stock soaring following a major deal with BeiGene for its DKN-01 antibody. The post Leap Therapeutics News: LPTX Stock Takes a Massive 58% Leap on BeiG...
Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.
About LPTX
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and ... [Read more...]
| Industry Biotechnology | Founded 2011 |
| Stock Exchange NASDAQ | Ticker Symbol LPTX |
Analyst Forecasts
According to 5 analysts, the average rating for LPTX stock is "Buy." The 12-month stock price forecast is 4.80, which is an increase of 240.43% from the latest price.